These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
418 related articles for article (PubMed ID: 34413145)
1. CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of Farwell MD; Gamache RF; Babazada H; Hellmann MD; Harding JJ; Korn R; Mascioni A; Le W; Wilson I; Gordon MS; Wu AM; Ulaner GA; Wolchok JD; Postow MA; Pandit-Taskar N J Nucl Med; 2022 May; 63(5):720-726. PubMed ID: 34413145 [TBL] [Abstract][Full Text] [Related]
2. First-in-Humans Imaging with Pandit-Taskar N; Postow MA; Hellmann MD; Harding JJ; Barker CA; O'Donoghue JA; Ziolkowska M; Ruan S; Lyashchenko SK; Tsai F; Farwell M; Mitchell TC; Korn R; Le W; Lewis JS; Weber WA; Behera D; Wilson I; Gordon M; Wu AM; Wolchok JD J Nucl Med; 2020 Apr; 61(4):512-519. PubMed ID: 31586002 [TBL] [Abstract][Full Text] [Related]
9. Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2. Wichmann CW; Burvenich IJG; Guo N; Rigopoulos A; McDonald A; Cao D; O'Keefe GJ; Gong SJ; Gan HK; Scott FE; Pore N; Coats S; Scott AM Nucl Med Biol; 2023; 122-123():108366. PubMed ID: 37473513 [TBL] [Abstract][Full Text] [Related]
10. Phase I/IIa PET imaging study with Joraku A; Hatano K; Kawai K; Kandori S; Kojima T; Fukumitsu N; Isobe T; Mori Y; Sakata M; Hara T; Nasu K; Minami M; Iizumi Y; Nishiyama H Ann Nucl Med; 2019 Feb; 33(2):119-127. PubMed ID: 30406361 [TBL] [Abstract][Full Text] [Related]
11. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891 [TBL] [Abstract][Full Text] [Related]
12. Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. Beckford Vera DR; Smith CC; Bixby LM; Glatt DM; Dunn SS; Saito R; Kim WY; Serody JS; Vincent BG; Parrott MC PLoS One; 2018; 13(3):e0193832. PubMed ID: 29513764 [TBL] [Abstract][Full Text] [Related]
13. Immuno-PET imaging of tumor endothelial marker 8 (TEM8). Kuo F; Histed S; Xu B; Bhadrasetty V; Szajek LP; Williams MR; Wong K; Wu H; Lane K; Coble V; Vasalatiy O; Griffiths GL; Paik CH; Elbuluk O; Szot C; Chaudhary A; St Croix B; Choyke P; Jagoda EM Mol Pharm; 2014 Nov; 11(11):3996-4006. PubMed ID: 24984190 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP). Nakaigawa N; Hasumi H; Utsunomiya D; Yoshida K; Ishiwata Y; Oka T; Hayward C; Makiyama K Jpn J Clin Oncol; 2024 Aug; 54(8):873-879. PubMed ID: 38864246 [TBL] [Abstract][Full Text] [Related]
15. ImmunoPET imaging of tissue factor expression in pancreatic cancer with Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831 [TBL] [Abstract][Full Text] [Related]
20. In Vitro and In Vivo Characterization of Allen KJH; Jiao R; Li J; Beckford-Vera DR; Dadachova E Molecules; 2022 Oct; 27(19):. PubMed ID: 36235126 [No Abstract] [Full Text] [Related] [Next] [New Search]